Search results
Jun 20, 2024 · Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) constitutes a distinctive cytogenetic entity associated with challenging outcomes, particularly in adult patients.
2 days ago · Philadelphia chromosome-positive acute lymphoblastic leukemia(Ph + ALL) accounts for approximately 25–30% of young patients with ALL and 40–50% of elderly patients with ALL. It is characterised by the translocation of chromosomes 9 and 22 and the formation of BCR::ABL1 fusion genes [ 1 , 2 ].
Jun 12, 2024 · Philadelphia chromosome-positive (Ph +) leukemia is a myeloproliferative neoplasm characterized by the reciprocal translocation between the long arms of chromosomes 9 and 22, t (9;22) (q34.1; q11.2) (de Klein et al., 1982; Deininger et al., 2000).
Jun 12, 2024 · Adding blinatumomab to tyrosine kinase inhibitors and steroids significantly improved the response rates and survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Regimens with ponatinib elicited higher molecular response rates than those with other tyrosine kinase inhibitors.
Jun 18, 2024 · Measurable residual disease (MRD) is integral in the management of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). This review discusses the current methods used to evaluate MRD as well as the interpretation, significance, and incorporation of MRD in current practice.
Jun 13, 2024 · For patients with Philadelphia chromosome (Ph)-positive and Ph-like leukaemias, similar block-based treatment regimens are used and include tyrosine kinase inhibitors (TKIs).
Jun 14, 2024 · Chronic myeloid leukaemia (CML) is a myeloproliferative neoplasm that originates from haematopoietic stem cells and is characterised by a chromosomal translocation t (9;22) (q34;q11.2), which forms the Philadelphia chromosome (Ph) containing the BCR::ABL1 fusion gene [ 1 ].
